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surements were only made when a steady state was achieved), the
resulting repeated CO measurements were closely correlated
(R¼0.93; ICC¼0.96). In regards to AVA, although there was good
correlation in AVA calculated from repeated assumed VO2 CO
(R¼0.85; ICC¼0.89) and TD CO (R¼ 0.93; ICC¼0.94), AVA based on
direct VO2 CO was very reproducible (R¼0.99;ICC>0.99).
CONCLUSIONS Cardiac output and AVA calculated from directly
measured VO2 varies substantially from those based on assumed VO2
values and thermodilution, which are the default methods used in
most CCL. Directly measured VO2-derived CO gives highly reproduc-
ible valve area measurements and may be more accurate.
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BACKGROUND Patients with severe aortic stenosis (AS) who are un-
suitable for surgical aortic valve replacement have historically been
treated with balloon aortic valvuloplasty (BAV). Subsequent to the
introduction of transcatheter aortic valve replacement (TAVR) for
high risk patients, BAV became an option as a bridge to TAVR. We
sought to describe the baseline clinical characteristics and outcomes
of patients undergoing BAV after the introduction of TAVR.
METHODS We identiﬁed 644 patients undergoing BAV from 2007 to
2012 at Mount Sinai. We compared clinical and procedural character-
istics, in-hospital outcomes, and mortality at 1-year in patients un-
dergoing BAV pre and post-introduction of TAVR.
RESULTS Patients undergoing BAV pre-TAVR (n ¼ 412, 64%) had a
signiﬁcantly higher incidence of prior cerebrovascular accident and
cardiovascular disease (Figure 1). These patients also had a higher
presentation of cardiogenic shock (6.3% vs. 2.6%, p<.01) and frailty
indicators, evidenced by more nursing home residents (5.8% vs. 1.7%,
p<.02), and dependency for all activities of daily living (ADLs) (12.6%
vs. 0.9%, p < .001). There was a slight, somewhat signiﬁcant decrease
in mortality at 1-year (pre-TAVR 28.5% vs. post-TAVR introduction
25.3%, p ¼ 0.09).CONCLUSIONS The introduction of TAVR has signiﬁcantly impacted
patient selection for BAV. Whether the observed mortality beneﬁt
post-introduction of TAVR is attributable to patient risk proﬁle or the
contribution of TAVR warrants further investigation.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) is an
established treatment in in-operable and high-risk patients with se-
vere symptomatic aortic stenosis. The current guidelines for TAVR are
to upsize transcatheter aortic valve (TAV) relative to the native
annulus to secure the device and minimize paravalvular leakage. The
range of annulus size for TAVR suggests that not all patients will
achieve complete TAV expansion to the manufactured size, and some
degree of incomplete stent expansion may exist. In addition, aortic
annulus is elliptical rather than circular, and non-circular TAV
deployment has been observed following TAVR. Nevertheless, the
clinical importance of TAV under-expansion or eccentricity, and their
impact on the long-term valve durability is unknown. The aim of this
study was to determine the synergistic impact of eccentric and
incomplete stent deployment on TAV leaﬂet stress distribution under
dynamic loading.
METHODS A 23mm TAV was created based on the Edwards SAPIEN
XT. The TAV was crimped and balloon-expanded in an acrylic tem-
plate to reach eccentricity of 0.0, 0.5 and 0.75 in the presence of none
(0 mm), mild (2 mm), and moderate (4 mm) valve oversizing. Leaﬂet
geometry in each conﬁguration was obtained using 3D Laser Scanner.
Furthermore, a biaxial stretching system was used to determine me-
chanical properties of the bovine pericardium patch used to create the
23mm TAV. The resultant stress-strain data was then ﬁt to the Fung’s
strain energy function to consider material anisotropy. A large
deformation analysis was performed using ABAQUS/Explicit package.
A transvalvular pressure waveform measured from in-vitro tests in a
pulse duplicator was applied to the leaﬂets.
RESULTS After complete expansion of the TAV to 23mm with zero
eccentricity, high stress regions were observed primarily in the com-
missures during diastole, and the maximum principal stress reached
to 2.52MPa. However, after incomplete expansion of the 23mm TAV to
diameters of 21 and 19mm with no eccentricity, the maximum prin-
cipal stress in the fully-closed position reached to 3.53MPa in the
commissures, and 2.60MPa in the belly region, respectively. On the
other hand, in the presence of 0.5 eccentricity, the maximum prin-
cipal stress in the commissures was increased by 56%, 95%, and 32%,
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tively. In addition, in the presence of 0.75 eccentricity, the maximum
principal stress value in the commissures was increased by 173%, 213%
and 149%, as compared to circular TAV expanded to 23, 21, and 19mm,
respectively.
CONCLUSIONS Computational models were developed to study the
synergistic impact of incomplete and eccentric TAV stent expansion on
leaﬂet stress distributions. Eccentric and incomplete stent deployment
induce localized high stress regions within the TAV leaﬂets. Increased
mechanical stress on TAV leaﬂets may lead to accelerated tissue
degeneration and diminished long-term valve durability.
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BACKGROUND The sequential implantation of a transcatheter heart
valve (THV) within a similar device, also known as valve-in-valve-in-
valve, will be an important concept in the future, considering patients
with elevated surgical risk and failed THVs within surgical aortic
valves (SAV). However, this procedure has not been studied in depth,
especially considering the reduction of effective oriﬁce area (EOA) and
the elevation of transvalvular gradients (DP). Our objective was to
evaluate the hydrodynamic performance of valve-in-valve-in-valve,
determining the therapeutic limits.
METHODS Using a pulse duplicator, three sets of valve-in-valve-in-
valve were tested. FDA speciﬁcations for cardiac output, mean arterial
pressure and heart rate variation were used. EOA and DP were
measured. First set was a 23mm surgical valve with two sequential
THV implants of 22mm and 20mm. Second set was a 25mm surgical
valve with two sequential THV implants of 24mm and 22mm. The last
set was a 25mm surgical valve with three sequential implants of
24mm, 22mm and 20mm.
RESULTS The results obtained from the three sets are represented on
Table 1.EOA (cm2) DP (mmHg)20mm THV within 22mm THV
within 23mm SAV0.97 12.822mm THV within 24mm THV
within 25mm SAV0.97 13.4620mm THV within 22mm THV
within 24mm THV within
25mm SAV0.86 15.32CONCLUSIONS The use of multiple THVs as an alternative to
repeated conventional aortic valve replacement can be considered
feasible after hydrodynamic testing. Satisfactory results can be ob-
tained with up to 22mm THVs. When a 20mm THV was needed, re-
sults were borderline to prohibitive, depending on whether it was the
2nd or 3rd implantation. The less-than-optimal results might be due to
device underexpansion.
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BACKGROUND There is limited data, especially from the US, on sex-
related differences with regards to patient characteristics and out-
comes with the CoreValve prosthesis. The objective of this study is to
compare the baseline characteristics and clinical outcomes in women
and men undergoing transcatheter aortic valve replacement with the
CoreValve prosthesis in the United States.
METHODS Patients used for this analysis include all patients who
underwent TAVR in any one of the 4 CoreValve US trials- the Cor-
eValve Pivotal extreme and high risk trials as well as the CoreValve
Continued Access extreme and high risk trials. Data from 3687 pa-
tients including 1708 women and 1979 men undergoing TAVR were
included for analysis.
RESULTS Women comprised 46% of the ﬁnal cohort and at baseline
had a higher STS score (9.6% vs. 8.3%). While there was no difference
in baseline NYHA classiﬁcation, women tended to have fewer cardiac
comorbidities and a lower rate of coronary artery disease including
fewer MIs, CABGs, and PCIs. Women were also less likely to have
peripheral vascular disease, a pre-existing pacemaker, or a prior
stroke. Conversely, women had increased frailty indices as measured
by KATZ ADL deﬁcits, walk times, and grip strength. At baseline
women had a higher mean gradient across the aortic valve (51.5 vs
44.3mmHg) and smaller EOA (0.66 vs. 0.79cm2). From a procedural
standpoint, women were slightly more likely to require alternative
access (21% vs 18.35%) and tended to receive smaller sized valves. The
30-day and 1-year outcomes are summarized in the table below.
CONCLUSIONS Women, who account for nearly half of the population
undergoing TAVR within the CoreValve US trials, tend to have fewer
cardiac comorbidities and increased frailty as compared to men. While
differences exist in procedural risks between men and women un-
dergoing TAVR with the CoreValve prosthesis, there was no difference
in 30-day or 1-year mortality.30 -days 1 yearMale
(N[1979)Female
(N[1708) P-valueMale
(N[1979)Female
(N[1708) P-valueAll-Cause Mortality, % 114 (5.8) 100 (5.9) 0.87 406 (24.1) 315 (21.3) 0.08Cardiovascular, % 109 (5.6) 98 (5.8) 0.74 305 (18.1) 242 (16.4) 0.23Stroke, % 79 (4.0) 95 (5.7) 0.02 129 (7.7) 141 (9.3) 0.05Major, % 42 (2.1) 60 (3.6) 0.01 72 (4.5) 86 (5.6) 0.04All-Cause Mortality or
Major Stroke, %142 (7.2) 140 (8.2) 0.22 434 (25.6) 353 (23.4) 0.32Bleed, % 615 (31.2) 728 (42.7) <0.0001 694 (36.7) 781 (46.8) <0.0001Life-Threatening/
disabling, %200
(10.2)244 (14.3) 0.0001 261 (14.3) 290 (17.9) 0.002Major Vascular
Complication, %96 (4.9) 165 (9.7) <0.0001 103 (5.3) 168 (9.9) <0.0001Acute Kidney Injury, % 222 (11.3) 175 (10.4) 0.38 222 (11.3) 175 (10.4) 0.38Myocardial Infarction,
%16 (0.8) 18 (1.1) 0.43 33 (2.1) 34 (2.4) 0.52Cardiac Tamponade, % 11 (0.6) 42 (2.5) <0.0001 15 (0.8) 43 (2.5) <0.0001New Permanent
Pacemaker
Implant, %453 (23.2) 311 (18.6) 0.0007 508
(27.0)346 (21.4) 0.0001KCCQ Overall
Summary Score
Change from
Baseline22.4 
27.422.4 
27.20.96 28.0 
28.128.9 
26.40.53
